Prodrug strategies to overcome poor water solubility

Advanced Drug Delivery Reviews

Volumn 59, Issue 7, 2007, Pages 677-694

  Stella, Valentino J ^a   Nti Addae, Kwame W ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

Bioreversible; Ionizable and non ionizable promoeities; Novel strategy; Oral delivery; Parenteral; Phosphates; Prodrug; Solubility

Indexed keywords

BIOREVERSIBLE; IONIZABLE PROMOEITIES; NON IONIZABLE PROMOEITIES; ORAL DELIVERY;

DRUG DELIVERY; MOLECULAR WEIGHT; PHOSPHATES; SOLUBILITY;

DRUG PRODUCTS;

5,6,7,13 TETRAHYDRO 12 (3 HYDROXYPROPYL) 9 ISOPROPOXYMETHYLINDENO[2,1 A]PYRROLO[3,4 C]CARBAZOL 5(12H) ONE; 5,6,7,13 TETRAHYDRO 12 (3 HYDROXYPROPYL) 9 ISOPROPOXYMETHYLINDENO[2,1 A]PYRROLO[3,4 C]CARBAZOL 5(12H) ONE DIMETHYLGLYCINE ESTER; AMPRENAVIR; AMPRENAVIR PHOSPHATE; AQUAVAN; BORTEZOMIB; BUPURAVAQUONE; CAM 4451; CAM 5223; CELECOXIB; CLINDAMYCIN PHOSPHATE; ENTACAPONE; ESTRAMUSTINE PHOSPHATE; ETOPOSIDE DISODIUM PHOSPHATE; FOSPHENYTOIN SODIUM; KNI 727; KYNOSTATIN 272; LOXAPINE; MACROGOL 400; MEFENAMIC ACID; MIPROXIFENE PHOSPHATE; N GLYCYLCARBAMAZEPINE; NONSTEROID ANTIINFLAMMATORY AGENT; ORGANOPHOSPHATE; PA 2808; PREDNISOLONE SODIUM PHOSPHATE; PRODRUG; PROPYLENE GLYCOL; STACHYFLIN PHOSPHATE; SULFOXIDE; SULINDAC; TOCOFERSOLAN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

DISSOLUTION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STRUCTURE; GASTROINTESTINAL TRACT; HUMAN; LIPID SOLUBILITY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

CHEMISTRY, PHARMACEUTICAL; DRUG ADMINISTRATION ROUTES; DRUG DESIGN; PRODRUGS; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; WATER;

EID: 34548024418     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2007.05.013     Document Type: Review

References (140)

1. In: Stella V.J., Borchardt R.T., Hageman M., Oliyai R., Maag H., and Tilley J. (Eds). Prodrugs: Challenges and rewards (2007), AAPS Press/SPringer
2. Testa B., and Mayer J.B. Hydrolysis in Drug and Prodrug Metabolism: Chemistry, Biochemistry and Enzymology (2003), Wiley-VCH
3. Ettmayer P., Amidon G.L., Clement B., and Testa B. Lessons learned from marketed and investigational prodrugs. J. Med. Chem. 47 10 (2004) 2393-2404
4. Testa B. Prodrug research: futile or fertile. Biochem. Pharmacol. 68 11 (2004) 2097-2106
5. In: Borchardt R.T., Kerns E.H., Hageman M.J., Thakker D.R., and Stevens J.L. (Eds). Optimizing the "Drug-Like" Properties of Leads in Drug Discovery (2006), AAPS Press/Springer
6. In: Borchardt R.T., Kerns E.H., Lipinski C.A., Thakker D.R., and Wang B. (Eds). Pharmaceutical Profiling in Drug Discovery for Lead Selection (2004), AAPS Press/Springer
7. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23 (1997) 3-25
8. Lipinski C.A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 44 1 (2000) 235-249
9. Horspool K.R., and Lipinski C.A. Advancing new drug delivery concepts to gain the lead. Drug Deliv. Tech. 3 7 (2003) 34-46
10. Di L., and Kerns E.H. Applications of physicochemical data to support lead optimization in drug teams. In: Borchardt R.T., Kerns E.H., Hageman M., Thakker D.R., and Stevens J.L. (Eds). Optimizing the "Drug-Like" Properties of Leads in Drug Discovery (2006), AAPS/Springer
11. Fleisher D., Bong R., and Stewart B.H. Improved oral drug delivery: solubility limitations overcome by the use of prodrugs. Adv. Drug Deliv. Rev. 19 2 (1996) 115-130
12. Hageman M.J. Solubility, solubilization and dissolution in drug delivery during lead optimization. In: Borchardt R.T., Edwards D.I., Hageman M.J., Thakker D.R., and Stevens J.L. (Eds). Optimizing the "Drug-Like" Properties of Leads in Drug Discovery (2006), AAPS Press/ Springer
13. Stella V.J. A case for prodrugs. In: Stella V.J., Borchardt R.T., Hageman M.J., Oliyai R., Maag H., and Tilley J. (Eds). Prodrugs: Challenges and Rewards (2007), AAPS Press/Springer
14. Martinez M.N., and Amidon G.L. A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J. Clin. Pharmacol. 42 6 (2002) 620-643
15. Horter D., and Dressman J.B. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv. Drug Deliv. Rev. 46 (2001) 75-87
16. Nicolaides E., Symillides M., Dressman J.B., and Reppas C. Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration. Pharm. Res. 18 3 (2001) 380-388
17. Perez de la Cruz Moreno M., Oth M., Deferme S., Lammert F., Tack J., Dressman J., and Augustijns P. Characterization of fasted-state human intestinal fluids collected from duodenum and jejunum. J. Pharm. Pharmacol. 58 8 (2006) 1079-1089
18. Hildebrand J.H. Solutions of nonelectrolytes. Annu. Rev. Phys. Chem. 1 (1950) 75-92
19. Duggan D.E., Hooke K.F., and Hwang S.S. Kinetics of the tissue distributions of sulindac and metabolites. Relevance to sites and rates of bioactivation. Drug Metab. Dispos. 8 4 (1980) 241-246
20. Dominguez L., Fagiolino P., Gordon S., and Manta E. Bioavailability comparison between albendazole and albendazole sulfoxide in rats and man. Farmaco 50 10 (1995) 697-702
21. Heimbach T., Oh D.M., Li L.Y., Forsberg M., Savolainen J., Leppaenen J., Matsunaga Y., Flynn G., and Fleisher D. Absorption rate limit considerations for oral phosphate prodrugs. Pharm. Res. 20 6 (2003) 848-856
22. Heimbach T., Fleisher D., and Kaddoumi A. Overcoming poor aqueous solubility of drugs for oral delivery. In: Stella V., Borchardt R.T., Hageman M., Oliyai R., Maag H., and Tilley J. (Eds). Prodrugs: Challenges and Rewards (2007), AAPS/ Springer
23. Fleisher D., Stewart B.H., and Amidon G.L. Design of prodrugs for improved gastrointestinal absorption by intestinal enzyme targeting. Methods Enzymol. 112 (1985) 360-381
24. Sohma Y., Hayashi Y., Ito T., Matsumoto H., Kimura T., and Kiso Y. Development of water-soluble prodrugs of the HIV-1 protease inhibitor KNI-727: importance of the conversion time for higher gastrointestinal absorption of prodrugs based on spontaneous chemical cleavage. J. Med. Chem. 46 19 (2003) 4124-4135
25. Vierling P., and Greiner J. Prodrugs of HIV protease inhibitors. Curr. Pharm. Des. 9 22 (2003) 1755-1770
26. Falcoz C., Jenkins J.M., Bye C., Hardman T.C., Kenney K.B., Studenberg S., Fuder H., and Prince W.T. Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers. J. Clin. Pharmacol. 42 8 (2002) 887-898
27. Brouwers J., Tack j., and Augustijns P. In vitro behavior of a phosphate ester prodrug of amprenavir in human intestinal fluids and in the caco-2 system: Illustration of intraluminal supersaturation. Int. J. Pharm. 366 2 (2007) 302-309
28. Fischer J.H., Patel T.V., and Fischer P.A. Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures. Clin. Pharmacokinet. 42 1 (2003) 33-58
29. Stella V.J. A case for prodrugs: fosphenytoin. Adv. Drug Deliv. Rev. 19 2 (1996) 311-330
30. Varia S.A., Schuller S., Sloan K.B., and Stella V.J. Phenytoin prodrugs. III: water-soluble prodrugs for oral and/or parenteral use. J. Pharm. Sci. 73 8 (1984) 1068-1073
31. Varia S.A., Schuller S., and Stella V.J. Phenytoin prodrugs. IV: hydrolysis of various 3-(hydroxymethyl)phenytoin esters. J. Pharm. Sci. 73 8 (1984) 1074-1080
32. Varia S.A., and Stella V.J. Phenytoin prodrugs. V: in vivo evaluation of some water-soluble phenytoin prodrugs in dogs. J. Pharm. Sci. 73 8 (1984) 1080-1087
33. Varia S.A., and Stella V.J. Phenytoin prodrugs. VI: in vivo evaluation of a phosphate ester prodrug of phenytoin after parenteral administration to rats. J. Pharm. Sci. 73 8 (1984) 1087-1090
34. Burstein A.H., Cox D., Mistry B., and Eddington N. Phenytoin pharmacokinetics following oral administration of phenytoin suspension and fosphenytoin solution to rats. Epilepsy Res. 34 (1999) 129-133
35. Stella V.J., Martodihardjo S., and Rao V.M. Aqueous solubility and dissolution rate does not adequately predict in vivo performance: a probe utilizing some n-acyloxymethyl phenytoin prodrugs. J. Pharm. Sci. 88 8 (1999) 775-779
36. Stella V.J., Martodihardjo S., Terada K., and Rao V.M. Some relationships between the physical properties of various 3-acyloxymethyl prodrugs of phenytoin to structure: potential in vivo performance implications. J. Pharm. Sci. 88 10 (1999) 1100
37. Stella V.J., Martodihardjo S., Terada K., and Rao V.M. Some relationships between the physical properties of various 3-acyloxymethyl prodrugs of phenytoin to structure: potential in vivo performance implications. J. Pharm. Sci. 87 10 (1998) 1235-1241
38. Yamaoka Y., Roberts R.D., and Stella V.J. Low-melting phenytoin prodrugs as alternative oral delivery modes for phenytoin: a model for other high-melting sparingly water-soluble drugs. J. Pharm. Sci. 72 4 (1983) 400-405
39. Shaw K.J., Erhardt P.W., Hagedom A.A., Pease C.A., Ingebretsen W.R., and Wiggins J.R. Cardiotonic agents. 7. Prodrug derivatives of 4-ethyl-1,3-dihydro-5-[4-(2-methyl-1H-imidazol-1-yl)benzoyl]-2H-imidazol-2-one. J. Med. Chem. 35 7 (1992) 1267-1272
40. Greenwald R.B., Choe Y.H., McGuire J., and Conover C.D. Effective drug delivery by pegylated drug conjugates. Adv. Drug Deliv. Rev. 55 2 (2003) 217-250
41. Greenwald R.B., Conover C.D., and Choe Y.H. Poly(ethylene glycol) conjugated drugs and prodrugs: a comprehensive review. Crit. Rev. Ther. Drug Carr. Syst. 17 2 (2000) 101-161
42. Greenwald R.B., and Zhao H. Poly(ethylene gylcol) prodrugs: altered pharmacokinetics and pharmacodynamics. In: Stella Valentino J., Borchardt R.T., Hageman M., Oliyai R., Maag H., and Tilley J. (Eds). Prodrugs: Challenges and Rewards (2007), AAPS Press/Springer
43. Schywalsky M., Ihmsen H., Tzabazis A., Fechner J., Burak E., Vornov J., and Schwilden H. Pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 in rats. Eur. J. Anaesthesiol. 20 3 (2003) 182-190
44. Fechner J., Ihmsen H., Hatterscheid D., Schiessl C., Vornov J.J., Burak E., Schwilden H., and Schuettler J. Pharmacokinetics and clinical pharmacodynamics of the new propofol prodrug GPI 15715 in volunteers. Anesthesiology 99 2 (2003) 303-313
45. Gibiansky E., Struys M.M.R.F., Gibiansky L., Vanluchene A.L.G., Vornov J., Mortier E.P., Burak E., and Van Bortel L. Aquavan injection, a water-soluble prodrug of propofol, as a bolus injection: a phase I dose-escalation comparison with diprivan (part 1): pharmacokinetics. Anesthesiology 103 4 (2005) 718-729
46. Struys M.M.R.F., Vanluchene A.L.G., Gibiansky E., Gibiansky L., Vornov J., Mortier E.P., and Van Bortel L. Aquavan injection, a water-soluble prodrug of propofol, as a bolus injection: a phase I dose-escalation comparison with diprivan (Part 2): pharmacodynamics and safety. Anesthesiology 103 4 (2005) 730-743
47. Hanson B.A., Schowen R.L., and Stella V.J. A mechanistic and kinetic study of the e-ring hydrolysis and lactonization of a novel phosphoryloxymethyl prodrug of camptothecin. Pharm. Res. 20 7 (2003) 1031-1038
48. Kearney A.S., and Stella V.J. Hydrolysis of pharmaceutically relevant phosphate monoester monoanions: correlation to an established structure-reactivity relationship. J. Pharm. Sci. 82 1 (1993) 69-72
49. Kearney A.S., and Stella V.J. The in vitro enzymic labilities of chemically distinct phosphomonoester prodrugs. Pharm. Res. 9 4 (1992) 497-503
50. Hemenway J., and Stella V. Prodrugs and parenteral drug delivery. In: Stella V., Borchardt R.T., Hageman M., Oliyai R., Maag H., and Tilley J. (Eds). Prodrugs: Challenges and Rewards (2007), AAPS Press/ Springer
51. Melby J.C., and Cyr M.St. Comparative studies on absorption and metabolic disposal of water-soluble corticosteroid esters. Metab. Clin. Exp. 10 (1961) 75-82
52. Derendorf H., Moellmann H., Rohdewald P., Rehder J., and Schmidt E.W. Kinetics of methylprednisolone and its hemisuccinate ester. Clin. Pharmacol. Ther. 37 5 (1985) 502-507
53. Moellmann H., Rohdewald P., Barth J., Moellmann C., Verho M., and Derendorf H. Comparative pharmacokinetics of methylprednisolone phosphate and hemisuccinate in high doses. Pharm. Res. 5 8 (1988) 509-513
54. Burke J.T., Wargin W.A., Sherertz R.J., Sanders K.L., Blum M.R., and Sarubbi F.A. Pharmacokinetics of intravenous chloramphenicol sodium succinate in adult patients with normal renal and hepatic function. J. Pharmacokinet. Biopharm. 10 6 (1982) 601-614
55. Kauffman R.E., Thirumoorthi M.C., Buckley J.A., Aravind M.K., and Dajani A.S. Relative bioavailability of intravenous chloramphenicol succinate and oral chloramphenicol palmitate in infants and children. J. Pediatr. 99 6 (1981) 963-967
56. V.J. Stella, J.J. Zygmunt, I.G. Georg, M.S. Safadi, Water-soluble prodrugs of hindered alcohols or phenols, United States patent US 19980131385. 2005 Feb 17.
57. Hemenway J.N. Preparation, Physicochemical Properties and Animal Studies of New Water-Soluble Prodrugs of Carbamazepine and Oxcarbazepine (2006), The University of Kansas, Lawrence (KS)
58. J. Hemenway, K.W. Nti-Addae, V.R. Guarino, J. Stella Valentino, Preparation, characterization and in vivo conversion of new water-soluble sulfenamide prodrugs of carbamazepine, Bioorg. Med. Chem. Lett. (submitted for publication).
59. V.R. Guarino, V. Karunaratne, V.J. Stella, Novel sulfenamide prodrugs of N-H bond-containing compounds, United States patent application WO2002US32957, 2003 April 24.
60. Guarino V.R. Sulfenamide Prodrugs: A novel Prodrug Approach for Amides, Imides and Other NH-acidic Compounds (2004), The University of Kansas, Lawrence (KS)
61. Guarino V.R., and Stella V.J. Prodrugs of amides, imides and other NH acid compounds. In: Stella Valentino J., Borchardt R.T., Hageman M., Oliyai R., Maag H., and Tilley J. (Eds). Prodrugs: Challenges and Rewards - Part 2 (2007), AAPS Press/Springer
62. Narisawa S., and Stella V.J. Increased shelf-life of fosphenytoin: solubilization of a degradant, phenytoin, through complexation with (SBE) 7M-b-CD. J. Pharm. Sci. 87 8 (1998) 926-930
63. Anderson B.D., Conradi R.A., Knuth K.E., and Nail S.L. Strategies in the design of solution-stable, water-soluble prodrugs. II: properties of micellar prodrugs of methylprednisolone. J. Pharm. Sci. 74 4 (1985) 375-381
64. Anderson B.D., Conradi R.A., Spilman C.H., and Forbes A.D. Strategies in the design of solution-stable, water-soluble prodrugs. III: influence of the pro-moiety on the bioconversion of 21-esters of corticosteroids. J. Pharm. Sci. 74 4 (1985) 382-387
65. Anderson B.D., Conradi R.A., and Johnson K. Influence of premicellar and micellar association on the reactivity of methylprednisolone 21-hemiesters in aqueous solution. J. Pharm. Sci. 72 4 (1983) 448-454
66. Wu S., Waugh W., and Stella V.J. Degradation pathways of a peptide boronic acid derivative, 2-Pyz-(CO)-Phe-Leu-b(OH)2. J. Pharm. Sci. 89 6 (2000) 758-765
67. L. Plamondon, L. Grenier, J. Adams, S.L. Gupta. Lyophilized formulation of boronic acid compounds, United States patent WO 2002059131, 2004 Aug 1.
68. VelcadeTM (bortezomib). Millennium pharmaceuticals, Inc. US Food and Drug Administration package insert. http://www.fda.gov/cder/foi/label/2003/021602lbl.pdf
69. Hedge S., and SChmidt M. To market, to market-2005. In: Wood A. (Ed). Annu. Rep. Med. Chem. (2006), Academic Press
70. Stella V.J. Prodrugs as therapeutics. Exp. Opin. Ther. Pat. 14 3 (2004) 277-280
71. Hanson B.A. Evaluation of a Phosphoryloxymethyl (POM) Prodrug of Camptothecin: Preformulation, Formulation and Pharmacokinetic Studies (2002), University of Kansas, Lawrence (KS)
72. Raub T.J. P-glycoprotein recognition of substrates and circumvention through rational drug design. Mol. Pharmacol. 3 1 (2006) 3-25
73. Stouch T.R., and Gudmundsson O. Progress in understanding the structure-activity relationships of [drugs interacting with] P-glycoprotein. Adv. Drug Deliv. Rev. 54 3 (2002) 315-328
74. Hildebrand J.H., and Scott R.L. Entropy of solution of nonelectrolytes. J. Chem. Phys. 20 (1952) 1520-1521
75. Baker W.R., Cai S., Dimitroff M., Fang L., Huh K.K., Ryckman D.R., Shang X., Shawar R.M., and Therrien J.H. A prodrug approach toward the development of water soluble fluoroquinolones and structure-activity relationships of quinoline-3-carboxylic acids. J. Med. Chem. 47 19 (2004) 4693-4709
76. Becker S., and Thornton L. Fosamprenavir: advancing HIV protease inhibitor treatment options. Exp. Opin. Pharmacotherapy 5 9 (2004) 1995-2005
77. Furfine E.S., Baker C.T., Hale M.R., Reynolds D.J., Salisbury J.A., Searle A.D., Studenberg S.D., Todd D., Tung R.D., and Spaltenstein A. Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir. Antimicrob. Agents Chemother. 48 3 (2004) 791-798
78. Corbett A.H., and Kashuba A.D.M. Fosamprenavir. Curr. Opin. Invest. Drugs 3 3 (2002) 384-390
79. Wire M.B., Shelton M.J., and Studenberg S. Fosamprenavir: clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin. Pharmacokinet. 45 2 (2006) 137-168
80. Perry C.M., and McTavish D. Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs Aging 7 1 (1995) 49-74
81. Wadsten T., and Lindberg N.O. Polymorphism of estramustine. J. Pharm. Sci. 78 7 (1989) 563-566
82. Gray J.E., Weaver R.N., Moran J., and Feenstra E.S. Parenteral toxicity of clindamycin 2-phosphate in laboratory animals. Toxicol. Appl. Pharmacol. 27 2 (1974) 308-321
83. Novak E., Wagner J.G., and Lamb D.J. Local and systemic tolerance, absorption and excretion of clindamycin hydrochloride after intramuscular administration. Int. Z. Klin. Pharmakol. Ther. Toxikol. 3 3 (1970) 201-208
84. Maentylae A., Rautio J., Nevalainen T., Keski-Rahkonen P., Vepsaelainen J., and Jaervinen T. Design, synthesis and in vitro evaluation of novel water-soluble prodrugs of buparvaquone. Eur. J. Pharm. Sci. 23 2 (2004) 151-158
85. Yagi S., Ono J., Yoshimoto J., Sugita K.-I., Hattori N., Fujioka T., Fujiwara T., Sugimoto H., Hirano K., and Hashimoto N. Development of anti-influenza virus drugs I: improvement of oral absorption and in vivo anti-influenza activity of stachyflin and its derivatives. Pharm. Res. 16 7 (1999) 1041-1046
86. Gerber N., Mays D.C., Donn K.H., Laddu A., Guthrie R.M., Turlapaty P., Quon C.Y., and Rivenburg W.K. Safety, tolerance and pharmacokinetics of intravenous doses of the phosphate ester of 3-hydroxymethyl-5,5-diphenylhydantoin: a new prodrug of phenytoin. J. Clin. Pharmacol. 28 11 (1988) 1023-1032
87. Schacter L. Etoposide phosphate: what, why, where, and how?. Sem. Oncol. Nurs. 23 6, Suppl. 13 (1996) 1-7
88. Kreis W., Budman D.R., Vinciguerra V., Hock K., Baer J., Ingram R., Schacter L.P., and Fields S.Z. Pharmacokinetic evaluation of high-dose etoposide phosphate after a 2-hour infusion in patients with solid tumors. Cancer Chemother. Pharmacol. 38 4 (1996) 378-384
89. Fields S.Z., Budman D.R., Young R.R., Kreis W., Ingram R., Schulman P., Cherny R.C., Wright J., Behr J., Snow C., and Schacter L.P. Phase I study of high-dose etoposide phosphate in man. Bone Marrow Transplant. 18 5 (1996) 851-856
90. Chan O.H., Schmid H.L., Stilgenbauer L.A., Howson W., Horwell D.C., and Stewart B.H. Evaluation of a targeted prodrug strategy to enhance oral absorption of poorly water-soluble compounds. Pharm. Res. 15 7 (1998) 1012-1018
91. Mamidi R.N.V.S., Mullangi R., Kota J., Bhamidipati R., Khan A.A., Katneni K., Datla S., Singh S.K., Rao K.Y., Rao C.S., Srinivas N.R., and Rajagopalan R. Pharmacological and pharmacokinetic evaluation of celecoxib prodrugs in rats. Biopharm. Drug Dispos. 23 7 (2002) 273-282
92. Singh S.K., Vobbalareddy S., Kalleda S.R., Casturi S.R., Datla S.R., Mamidi R.N.V.S., Mullangi R., Ramanujam R., Yeleswarapu K.R., and Iqbal J. Identification of 2-hydroxymethyl-4-[5-(4-methoxyphenyl)-3-trifluoromethyl-pyrazol-1-yl]-n-propionylbenzenesulfonamide sodium as a potential COX-2 inhibitor for oral and parenteral administration. Bioorg. Med. Chem. 14 24 (2006) 8626-8634
93. Sohma Y., Hayashi Y., Skwarczynski M., Hamada Y., Sasaki M., Kimura T., and Kiso Y. O-N intramolecular acyl migration reaction in the development of prodrugs and the synthesis of difficult sequence-containing bioactive peptides. Biopolymers 76 4 (2004) 344-356
94. Hamada Y., Ohtake J., Sohma Y., Kimura T., Hayashi Y., and Kiso Y. New water-soluble prodrugs of hiv protease inhibitors based on O-N intramolecular acyl migration. Bioorg. Med. Chem. 10 12 (2002) 4155
95. Hamada Y., Matsumoto H., Kimura T., Hayashi Y., and Kiso Y. Effect of the acyl groups on O-N acyl migration in the water-soluble prodrugs of HIV-1 protease inhibitor. Bioorg. Med. Chem. Lett. 13 16 (2003) 2727-2730
96. Wiwattanawongsa K., Tantishaiyakul V., Lomlim L., Rojanasakul Y., Pinsuwan S., and Keawnopparat S. Experimental and computational studies of epithelial transport of mefenamic acid ester prodrugs. Pharm. Res. 22 5 (2005) 721-727
97. Ruggeri B., Singh J., Gingrich D., Angeles T., Albom M., Chang H., Robinson C., Hunter K., Dobrzanski P., Jones-Bolin S., Aimone L., Klein-Szanto A., Herbert J.-M., Bono F., Schaeffer P., Casellas P., Bourie B., Pili R., Isaacs J., Ator M., Hudkins R., Vaught J., Mallamo J., and Dionne C. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Cancer Res. 63 18 (2003) 5978-5991
98. Gingrich D.E., Reddy D.R., Iqbal M.A., Singh J., Aimone L.D., Angeles T.S., Albom M., Yang S., Ator M.A., Meyer S.L., Robinson C., Ruggeri B.A., Dionne C.A., Vaught J.L., Mallamo J.P., and Hudkins R.L. A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: Structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055. J. Med. Chem. 46 25 (2003) 5375-5388
99. Shen T.T., and Winter C.A. Chemical and biological studies on indomethacin, sulindac and their analogs. In: Harper N.J., and Simmonds A.B. (Eds). Advances in Drug Research (1977), Academic Press, London
100. Davies N.M., and Watson M.S. Clinical pharmacokinetics of sulindac. A dynamic old drug. Clin. Pharmacokinet. 32 6 (1997) 437-459
101. Godfraind T., Towse G., and Van Nueten J.M. Cinnarizine - a selective calcium entry blocker. Drugs Today 18 1 (1982) 27-42
102. Banaszczyk M.G., Carlo A.T., Millan V., Lindsey A., Moss R., Carlo D.J., and Hendler S.S. Propofol phosphate, a water-soluble propofol prodrug: in vivo evaluation. Aneth. Anal. 95 5 (2002) 1285-1292
103. Fechner J., Ihmsen H., Schiessl C., Jeleazcov C., Vornov J.J., Schwilden H., and Schuettler J. Sedation with GPI 15715, a water-soluble prodrug of propofol, using target-controlled infusion in volunteers. Aneth. Anal. 100 3 (2005) 701-706
104. Fleisher D., Johnson K.C., Stewart B.H., and Amidon G.L. Oral absorption of 21-corticosteroid esters: a function of aqueous stability and intestinal enzyme activity and distribution. J. Pharm. Sci. 75 10 (1986) 934-939
105. Bentley A., Butters M., Green S.P., Learmonth W.J., MacRae J.A., Morland M.C., O'Connor G., and Skuse J. The discovery and process development of a commercial route to a water soluble prodrug, fosfluconazole. Org. Process Res. Dev. 6 2 (2002) 109-112
106. Sobue S., Tan K., Layton G., Leclerc V., and Weil A. The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole. Br. J. Clin. Pharmacol. 57 6 (2004) 773-784
107. Ueda Y., Matiskella J.D., Golik J., Connolly T.P., Hudyma T.W., Venkatesh S., Dali M., Kang S.-H., Barbour N., Tejwani R., Varia S., Knipe J., Zheng M., Mathew M., Mosure K., Clark J., Lamb L., Medin I., Gao Q., Huang S., Chen C.-P., and Bronson J.J. Phosphonooxymethyl prodrugs of the broad spectrum antifungal azole, ravuconazole: synthesis and biological properties. Bioorg. Med. Chem. Lett. 13 21 (2003) 3669-3672
108. Arikan S., and Rex J.H. Ravuconazole. Curr. Opin. Investig. Drugs 3 4 (2002) 555-561
109. Krise J.P., Narisawa S., and Stella V.J. A novel prodrug approach for tertiary amines. 2. Physicochemical and in vitro enzymatic evaluation of selected N-phosphonooxymethyl prodrugs. J. Pharm. Sci. 88 9 (1999) 922-927
110. Krise J.P., Zygmunt J., Georg G.I., and Stella V.J. Novel prodrug approach for tertiary amines: synthesis and preliminary evaluation of N-phosphonooxymethyl prodrugs. J. Med. Chem. 42 16 (1999) 3094-3100
111. Mueller C., and Wollmann H. Stability of drugs and pharmaceuticals. 26 studies on the stability of drugs with medium stability. Pharmazie 41 1 (1986) 53
112. Abramson F.P., and Miller Jr. H.C. Bioavailability, distribution and pharmacokinetics of diethylstilbestrol produced from stilphostrol. J. Urol. 128 6 (1982) 1336-1339
113. Murdock K.C., Lee V.J., Citarella R.V., Durr F.E., Nicolau G., and Kohlbrenner M. N-phosphoryl derivatives of bisantrene. Antitumor prodrugs with enhanced solubility and reduced potential for toxicity. J. Med. Chem. 36 15 (1993) 2098-2101
114. Powis G., and Kovach J.S. Disposition of bisantrene in humans and rabbits: evidence for intravascular deposition of drug as a cause of phlebitis. Cancer Res. 43 2 (1983) 925-929
115. Brockman R.W., Schabel F.M., and Montgomery J.A. Biologic activity of 9-b-d-arabinofuranosyl-2-fluoroadenine, a metabolically stable analog of 9-b-d-arabinofuranosyladenine. Biochem. Pharmacol. 26 22 (1977) 2193-2196
116. Plunkett W., Huang P., and Gandhi V. Metabolism and action of fludarabine phosphate. Sem. Oncol. Nurs. 17 5, Suppl. 8 (1990) 3-17
117. Leppanen J., Huuskonen J., Savolainen J., Nevalainen T., Taipale H., Vepsalainen J., Gynther J., and Jarvinen T. Synthesis of a water-soluble prodrug of entacapone. Bioorg. Med. Chem. Lett. 10 17 (2000) 1967
118. Pochopin N.L., Charman W.N., and Stella V.J. Amino acid derivatives of dapsone as water-soluble prodrugs. Int. J. Pharm. 121 2 (1995) 157-167
119. Pochopin N.L., Charman W.N., and Stella V.J. Pharmacokinetics of dapsone and amino acid prodrugs of dapsone. Drug Metab. Dispos. 22 5 (1994) 770-775
120. Talley J.J., Bertenshaw S.R., Brown D.L., Carter J.S., Graneto M.J., Kellogg M.S., Koboldt C.M., Yuan J., Zhang Y.Y., and Seibert K. N-[[(5-methyl-3-phenylisoxazol-4-yl)- phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: a potent and selective inhibitor of COX-2 for parenteral administration. J. Med. Chem. 43 9 (2000) 1661-1663
121. Prasit P., Wang Z., Brideau C., Chan C.C., Charleson S., Cromlish W., Ethier D., Evans J.F., Ford-Hutchinson A.W., Gauthier J.Y., Gordon R., Guay J., Gresser M., Kargman S., Kennedy B., Leblanc Y., Leger S., Mancini J., O'Neill G.P., Ouellet M., Percival M.D., Perrier H., Riendeau D., Rodger I., Tagari P., Therien M., Vickers P., Wong E., Xu L.J., Young R.N., Zamboni R., Boyce S., Rupniak N., Forrest M., Visco D., and Patrick D. The discovery of rofecoxib, [MK 966, Vioxx (R), 4-(4¢-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor. Bioorg. Med. Chem. Lett. 9 13 (1999) 1773
122. Penning T.D., Talley J.J., Bertenshaw S.R., Carter J.S., Collins P.W., Docter S., Graneto M.J., Lee L.F., Malecha J.W., Miyashiro J.M., Rogers R.S., Rogier D.J., Yu S.S., Anderson G.D., Burton E.G., Cogburn J.N., Gregory S.A., Koboldt C.M., Perkins W.E., Seibert K., Veenhuizen A.W., Zhang Y.Y., and Isakson P.C. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3- (trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, celecoxib),. J. Med. Chem. 40 9 (1997) 1347-1365
123. Sorbera L.A., Leeson P.A., Castaner J., and Castaner R.M. Valdecoxib and parecoxib sodium. Drugs Future 26 2 (2001) 133-140
124. Bundgaard H., Larsen C., and Thorbek P. Prodrugs as drug delivery systems. XXVI. Preparation and enzymic hydrolysis of various water-soluble amino acid esters of metronidazole. Int. J. Pharm. 18 1-2 (1984) 67-77
125. Bundgaard H., Jensen E., Falch E., and Pedersen S.B. Allopurinol prodrugs. V. Water-soluble N-substituted (aminomethyl)benzoyloxymethyl allopurinol derivatives for parenteral or rectal delivery. Int. J. Pharm. 64 1 (1990) 75-87
126. Bundgaard H., Jensen E., and Falch E. Water-soluble, solution-stable, and biolabile n-substituted (aminomethyl)benzoate ester prodrugs of acyclovir. Pharm. Res. 8 9 (1991) 1087-1093
127. Hayashi Y., Skwarczynski M., Hamada Y., Sohma Y., Kimura T., and Kiso Y. A novel approach of water-soluble paclitaxel prodrug with no auxiliary and no byproduct: design and synthesis of isotaxel. J. Med. Chem. 46 18 (2003) 3782-3784
128. Leu Y.L., Roffler S.R., and Chern J.W. Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (adept). J. Med. Chem. 42 18 (1999) 3623-3628
129. Prijovich Z.M., Leu Y.L., and Roffler S.R. Stability of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in the presence of human serum albumin. Biochem. Pharmacol. 66 7 (2003) 1181
130. V.J. Stella, P.E. Kennedy, Water-soluble rapamycin prodrugs, USA, Patent. 85-806152: 4650803, 19851206, 1987.
131. Supko J.G., and Malspeis L. Dose-dependent pharmacokinetics of rapamycin-28-n, n-dimethylglycinate in the mouse. Cancer Chemother. Pharmacol. 33 4 (1994) 325-330
132. Bhatt R., de Vries P., Tulinsky J., Bellamy G., Baker B., Singer J., and Klein P. Synthesis and in vivo antitumor activity of poly(l-glutamic acid) conjugates of 20(s)-camptothecin. J. Med. Chem. 46 1 (2003) 190-193
133. Slatter J.G., Schaaf L.J., Sams J.P., Feenstra K.L., Johnson M.G., Bombardt P.A., Cathcart K.S., Verburg M.T., Pearson L.K., Compton L.D., Miller L.L., Baker D.S., Pesheck C.V., and Lord R.S. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following i.v. Infusion of [14C]CPT-11 in cancer patients. Drug Metab. Dispos. 28 4 (2000) 423-433
134. Mussini E., Marcucci F., Fanelli R., Guaitani A., and Garattini S. Analytical and pharmacokinetic studies on the optical isomers of oxazepam succinate half-ester. Biochem. Pharmacol. 21 1 (1972) 127-129
135. Salmona M., Saronio C., Bianchi R., Marcucci F., and Mussini E. In vitro hydrolysis of oxazepam succinate half-ester by a stereospecific soluble esterase from different animal species. J. Pharm. Sci. 63 2 (1974) 222-225
136. Walkenstein S.S., Wiser R., Gudmundsen C.H., Kimmel H.B., and Corradino R.A. Absorption, metabolism, and excretion of oxazepam and its succinate half-ester. J. Pharm. Sci. 53 10 (1964) 1181-1186
137. Laubach G.D., P'an S.Y., and Rudel H.W. Steroid anesthetic agent. Science 122 (1955) 78
138. Murphy F.J., Quadagni N.P., and DeBon F. Use of steroid anesthesia in surgery. JAMA 158 (1955) 1412-1414
139. JEnsen E., and Bundgaard H. N-substituted (aminomethyl)benzoate 21-esters of corticosteroids as water-soluble, solution-stable and biolabile prodrugs. Acta Pharm. Nord. 4 1 (1992) 35-42
140. Anderson B.D., Conradi R.A., and Knuth K.E. Strategies in the design of solution-stable, water-soluble prodrugs. I: a physical-organic approach to pro-moiety selection for 21-esters of corticosteroids. J. Pharm. Sci. 74 4 (1985) 365-374